MCID: RHB003
MIFTS: 56

Rhabdomyosarcoma

Categories: Neuronal diseases, Rare diseases, Cancer diseases, Muscle diseases, Genetic diseases

Aliases & Classifications for Rhabdomyosarcoma

MalaCards integrated aliases for Rhabdomyosarcoma:

Name: Rhabdomyosarcoma 12 76 59 29 55 6 44 15 73

Characteristics:

Orphanet epidemiological data:

59
rhabdomyosarcoma
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3247
MeSH 44 D012208
NCIt 50 C3359
Orphanet 59 ORPHA780
UMLS via Orphanet 74 C0035412
ICD10 via Orphanet 34 C49.9
MESH via Orphanet 45 D012208
UMLS 73 C0035412

Summaries for Rhabdomyosarcoma

Disease Ontology : 12 A skeletal muscle cancer that arise from skeletal muscle progenitors.

MalaCards based summary : Rhabdomyosarcoma is related to rhabdomyosarcoma 2 and embryonal rhabdomyosarcoma. An important gene associated with Rhabdomyosarcoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and Transcriptional misregulation in cancer. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and prostate, and related phenotypes are cardiovascular system and integument

Wikipedia : 76 Rhabdomyosarcoma, or RMS, is an aggressive and highly malignant form of cancer that develops from... more...

Related Diseases for Rhabdomyosarcoma

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 316)
# Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 2 35.1 ALK FOXO1 MYOD1 PAX3 PAX7 RMST
2 embryonal rhabdomyosarcoma 35.1 DICER1 FOXO1 IGF2 MYOD1 PAX3 PAX7
3 botryoid rhabdomyosarcoma 35.0 MYOD1 PAX3
4 parameningeal embryonal rhabdomyosarcoma 34.9 ALK TP53
5 pleomorphic rhabdomyosarcoma 34.8 FOXO1 MYOD1 PAX3 PAX7
6 beckwith-wiedemann syndrome 33.4 IGF2 MYOD1 SLC22A18 TP53
7 rhabdoid cancer 31.3 IGF2 MYOD1 STIM1
8 cervical polyp 31.2 FHL2 MYOD1
9 ewing sarcoma 31.0 ALK FOXO1 IGF2 MYOD1 PAX3 PAX7
10 histiocytoma 30.8 ALK MYOD1 TP53
11 breast cancer 29.9 ALK BRCA1 FOXO1 IGF2 MIR206 MIR29B2
12 rhabdomyosarcoma, embryonal, 1 12.4
13 spindle cell rhabdomyosarcoma 12.3
14 prostate rhabdomyosarcoma 12.2
15 rhabdomyosarcoma, embryonal, 2 12.2
16 prostate embryonal rhabdomyosarcoma 12.2
17 liver rhabdomyosarcoma 12.2
18 orbit rhabdomyosarcoma 12.0
19 bile duct rhabdomyosarcoma 12.0
20 mediastinum rhabdomyosarcoma 12.0
21 anus rhabdomyosarcoma 12.0
22 breast rhabdomyosarcoma 12.0
23 orbit embryonal rhabdomyosarcoma 12.0
24 central nervous system rhabdomyosarcoma 11.9
25 gallbladder rhabdomyosarcoma 11.9
26 orbit alveolar rhabdomyosarcoma 11.9
27 rhabdomyosarcoma of the cervix uteri 11.9
28 vulvovaginal rhabdomyosarcoma 11.9
29 rhabdomyosarcoma of the corpus uteri 11.9
30 mixed type rhabdomyosarcoma 11.8
31 childhood pleomorphic rhabdomyosarcoma 11.8
32 embryonal extrahepatic bile duct rhabdomyosarcoma 11.8
33 rectum rhabdomyosarcoma 11.8
34 ovary rhabdomyosarcoma 11.8
35 testis rhabdomyosarcoma 11.8
36 childhood botryoid rhabdomyosarcoma 11.8
37 childhood vagina botryoid rhabdomyosarcoma 11.8
38 vulvar childhood botryoid-type embryonal rhabdomyosarcoma 11.8
39 vagina botryoid rhabdomyosarcoma 11.7
40 adult botryoid rhabdomyosarcoma 11.7
41 adult vagina botryoid rhabdomyosarcoma 11.7
42 li-fraumeni syndrome 11.3
43 ectomesenchymoma 11.2
44 rare adenocarcinoma of the breast 11.2 SLC22A18 TP53
45 li-fraumeni syndrome 2 11.1
46 cellular schwannoma 11.1 PAX3 PAX7 TP53
47 undifferentiated pleomorphic sarcoma 11.1
48 childhood kidney cell carcinoma 11.1 ALK FOXO1 PAX3
49 central nervous system mesenchymal non-meningothelial tumor 11.1 FOXO1 MYOD1 PAX3 PAX7
50 meninges sarcoma 11.1 IGF2 TP53

Graphical network of the top 20 diseases related to Rhabdomyosarcoma:



Diseases related to Rhabdomyosarcoma

Symptoms & Phenotypes for Rhabdomyosarcoma

MGI Mouse Phenotypes related to Rhabdomyosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 PAX3 STIM1 TP53 BRCA1 DICER1 FHL2
2 integument MP:0010771 10.03 ALK BRCA1 DICER1 FOXO1 IGF2 PAX3
3 muscle MP:0005369 9.97 BRCA1 DICER1 FOXO1 IGF2 MYOD1 PAX3
4 neoplasm MP:0002006 9.92 ALK BRCA1 DICER1 FOXO1 MYOD1 PAX3
5 limbs/digits/tail MP:0005371 9.88 BRCA1 DICER1 FOXO1 IGF2 PAX3 TP53
6 no phenotypic analysis MP:0003012 9.8 FOXO1 IGF2 MYOD1 PAX3 PAX7 TP53
7 normal MP:0002873 9.76 BRCA1 DICER1 FHL2 FOXO1 MYOD1 PAX3
8 respiratory system MP:0005388 9.61 ALK BRCA1 DICER1 IGF2 MYOD1 PAX3
9 skeleton MP:0005390 9.36 STIM1 TP53 ALK BRCA1 DICER1 FHL2

Drugs & Therapeutics for Rhabdomyosarcoma

Drugs for Rhabdomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
3
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
12
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
13
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
14
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
15
Morphine Approved, Investigational Phase 3,Phase 1,Phase 2 57-27-2 5288826
16
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
17
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
18
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
19
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
20
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
22
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
23
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
24
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
25
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
26
Captopril Approved Phase 3 62571-86-2 44093
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Ribavirin Approved Phase 3 36791-04-5 37542
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
31
Acyclovir Approved Phase 3 59277-89-3 2022
32
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
33
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
34
Idarubicin Approved Phase 3 58957-92-9 42890
35
Cyproheptadine Approved Phase 3 129-03-3 2913
36
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
37
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
38
Mycophenolic acid Approved Phase 3 24280-93-1 446541
39
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
40
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
41 Trofosfamide Investigational Phase 3 22089-22-1
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
45 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
46
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
48 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
49 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
50 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 276)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
4 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
5 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
6 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
8 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
9 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
12 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
13 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
14 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
15 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
16 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
17 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
18 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
19 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
20 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Recruiting NCT02567435 Phase 3 Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
21 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
22 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Active, not recruiting NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
23 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
24 Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood Terminated NCT00162695 Phase 3 Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
25 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
26 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
27 Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245089 Phase 2 cyclophosphamide;vincristine sulfate
28 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245141 Phase 2 cyclophosphamide;vincristine sulfate
29 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01216839 Phase 2 Everolimus
30 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
31 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
32 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
33 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
34 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
35 Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma Completed NCT00055939 Phase 2 exatecan mesylate
36 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
37 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
38 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Completed NCT00025363 Phase 2 vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
39 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Completed NCT01055314 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
40 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
41 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
42 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
43 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
44 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
45 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
46 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
47 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
48 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
49 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
50 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed

Search NIH Clinical Center for Rhabdomyosarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: rhabdomyosarcoma

Genetic Tests for Rhabdomyosarcoma

Genetic tests related to Rhabdomyosarcoma:

# Genetic test Affiliating Genes
1 Rhabdomyosarcoma 29

Anatomical Context for Rhabdomyosarcoma

MalaCards organs/tissues related to Rhabdomyosarcoma:

41
Bone, Bone Marrow, Prostate, Skeletal Muscle, Cervix, Brain, Nk Cells

Publications for Rhabdomyosarcoma

Articles related to Rhabdomyosarcoma:

(show top 50) (show all 2151)
# Title Authors Year
1
PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. ( 29898687 )
2018
2
Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols - A single institution report in Taiwan. ( 29903549 )
2018
3
Fusion-Negative Rhabdomyosarcoma Can Arise from Endothelial Cells. ( 29352048 )
2018
4
A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells inA vitro. ( 29907230 )
2018
5
Safety markers for rhabdomyosarcoma cells using an <i>in vivo</i> imaging system. ( 29963179 )
2018
6
Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. ( 29316425 )
2018
7
Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. ( 29940525 )
2018
8
Embryonal rhabdomyosarcoma of urinary bladder in an adult patient: an unusual manifestation. ( 29654103 )
2018
9
Uterine Rhabdomyosarcoma in Adults. ( 29320751 )
2018
10
Extracellular cholesterol oxidase production by Streptomyces aegyptia, in vitro anticancer activities against rhabdomyosarcoma, breast cancer cell-lines and in vivo apoptosis. ( 29426900 )
2018
11
Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes. ( 29972784 )
2018
12
Long-term results in children with head and neck rhabdomyosarcoma: A report from the Italian Soft Tissue Sarcoma Committee. ( 29115716 )
2018
13
Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype. ( 29758589 )
2018
14
Cytologic Diagnosis of Metastatic Alveolar Rhabdomyosarcoma in Cerebrospinal Fluid: A Case Report. ( 29902914 )
2018
15
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. ( 29941280 )
2018
16
Spindle cell rhabdomyosarcoma of the anterior mandible manifesting as a periapical lesion of pulpal origin: Case report. ( 29665230 )
2018
17
Cancer, Rhabdomyosarcoma ( 29939543 )
2018
18
Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging. ( 29368010 )
2018
19
Synchronous, but separate, bladder and vaginal rhabdomyosarcoma: a novel genetic case report. ( 29900825 )
2018
20
Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. ( 29956493 )
2018
21
Rhabdomyosarcoma in children - current pathologic and molecular classification. ( 29895123 )
2018
22
Giant intrascrotal embryonal rhabdomyosarcoma in an adult: a case report and review of theA literature. ( 29804543 )
2018
23
Poorly differentiated, ovarian Sertoli-Leydig cell tumor with heterologous rhabdomyosarcoma and glandular elements: Diagnosis and management of a rare neoplasm. ( 29922708 )
2018
24
Rhabdomyosarcoma Revealed by a Breast Metastasis. ( 29356738 )
2018
25
Alveolar paratesticular rhabdomyosarcoma mimicing epididymitis: Case report and literature review. ( 29924027 )
2018
26
Phacomatosis pigmentokeratotica: a case of HRAS mosaicism causing rhabdomyosarcoma. ( 29430633 )
2018
27
Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells. ( 29370118 )
2018
28
Metastatic rhabdomyosarcoma mimicking autoimmune pancreatitis diagnosed by EUS-guided fine-needle biopsy. ( 29627494 )
2018
29
Small round cell myofibroblastoma of the oral cavity: A tumor mimicking embryonal rhabdomyosarcoma. ( 29487010 )
2018
30
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. ( 29973406 )
2018
31
Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma. ( 29304781 )
2018
32
Vision loss secondary to orbital extension of rhabdomyosarcoma in an adult. ( 29424955 )
2018
33
More than Grapes and Bleeding: An Updated Look at Pelvic Rhabdomyosarcoma in Young Females. ( 29421342 )
2018
34
DICER1 mutation-positive Giant Botryoid Fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma. ( 29883781 )
2018
35
Pediatric Robotic Prostatectomy and Pelvic Lymphadenectomy for Embryonal Rhabdomyosarcoma. ( 29702157 )
2018
36
Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells. ( 29899822 )
2018
37
Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma. ( 29967215 )
2018
38
Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients. ( 29921891 )
2018
39
Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines. ( 29971532 )
2018
40
Corrigendum: Ermoian RP, Breneman J, Walterhouse DO, etA al. 45A Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12A weeks of ARST0331 chemotherapy. Pediatr Blood Cancer. 2017;64:E26540. https://doi.org/10.1002/pbc.26540. ( 29679530 )
2018
41
PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. ( 29367756 )
2018
42
SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. ( 29445192 )
2018
43
HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. ( 29362363 )
2018
44
Testicular transposition in children undergoing brachytherapy for bladder and/or prostate rhabdomyosarcoma. ( 29753523 )
2018
45
Lumbar Intraspinal Spindle Cell Rhabdomyosarcoma as a Rare Cause of Spinal Stenosis: A Case Report. ( 29452297 )
2018
46
Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. ( 29881993 )
2018
47
Prosthetic rehabilitation for a patient treated for embryonal rhabdomyosarcoma. ( 29551375 )
2018
48
Appraisal of the role of radical prostatectomy for rhabdomyosarcoma in children: oncological and urological outcome. ( 29899760 )
2018
49
Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach. ( 29404242 )
2018
50
Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma. ( 29468476 )
2018

Variations for Rhabdomyosarcoma

ClinVar genetic disease variations for Rhabdomyosarcoma:

6
(show all 12)
# Gene Variation Type Significance SNP ID Assembly Location
1 BRCA1 NM_007294.3(BRCA1): c.844_850dupTCATTAC (p.Gln284Leufs) duplication Pathogenic rs80357989 GRCh37 Chromosome 17, 41246698: 41246704
2 BRCA1 NM_007294.3(BRCA1): c.844_850dupTCATTAC (p.Gln284Leufs) duplication Pathogenic rs80357989 GRCh38 Chromosome 17, 43094681: 43094687
3 BRCA2 NM_000059.3(BRCA2): c.9874C> T (p.Pro3292Ser) single nucleotide variant Uncertain significance rs876660917 GRCh37 Chromosome 13, 32972524: 32972524
4 BRCA2 NM_000059.3(BRCA2): c.9874C> T (p.Pro3292Ser) single nucleotide variant Uncertain significance rs876660917 GRCh38 Chromosome 13, 32398387: 32398387
5 ALK NM_004304.4(ALK): c.3673G> A (p.Asp1225Asn) single nucleotide variant Pathogenic rs1057519696 GRCh37 Chromosome 2, 29436920: 29436920
6 ALK NM_004304.4(ALK): c.3673G> A (p.Asp1225Asn) single nucleotide variant Pathogenic rs1057519696 GRCh38 Chromosome 2, 29214054: 29214054
7 FGFR4 NM_213647.2(FGFR4): c.1605C> A (p.Asn535Lys) single nucleotide variant Likely pathogenic rs1057519792 GRCh37 Chromosome 5, 176522416: 176522416
8 FGFR4 NM_213647.2(FGFR4): c.1605C> A (p.Asn535Lys) single nucleotide variant Likely pathogenic rs1057519792 GRCh38 Chromosome 5, 177095415: 177095415
9 FGFR4 NM_213647.2(FGFR4): c.1605C> G (p.Asn535Lys) single nucleotide variant Likely pathogenic rs1057519792 GRCh37 Chromosome 5, 176522416: 176522416
10 FGFR4 NM_213647.2(FGFR4): c.1605C> G (p.Asn535Lys) single nucleotide variant Likely pathogenic rs1057519792 GRCh38 Chromosome 5, 177095415: 177095415
11 FGFR4 NM_213647.2(FGFR4): c.1649T> A (p.Val550Glu) single nucleotide variant Likely pathogenic rs1057519793 GRCh37 Chromosome 5, 176522552: 176522552
12 FGFR4 NM_213647.2(FGFR4): c.1649T> A (p.Val550Glu) single nucleotide variant Likely pathogenic rs1057519793 GRCh38 Chromosome 5, 177095551: 177095551

Cosmic variations for Rhabdomyosarcoma:

9
(show top 50) (show all 151)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10648 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 6
2 COSM10660 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.818G>A p.R273H 17:7673802-7673802 6
3 COSM45256 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.871A>C p.K291Q 17:7673749-7673749 6
4 COSM45005 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.739A>G p.N247D 17:7674224-7674224 6
5 COSM11081 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.733G>T p.G245C 17:7674230-7674230 6
6 COSM10662 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
7 COSM10813 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.394A>G p.K132E 17:7675218-7675218 6
8 COSM44536 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.728T>C p.M243T 17:7674235-7674235 6
9 COSM10654 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.637C>T p.R213* 17:7674894-7674894 6
10 COSM44720 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.961A>T p.K321* 17:7673567-7673567 6
11 COSM6932 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.733G>A p.G245S 17:7674230-7674230 6
12 COSM45253 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.611A>G p.E204G 17:7674920-7674920 6
13 COSM10725 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.701A>G p.Y234C 17:7674262-7674262 6
14 COSM45255 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.668C>G p.P223R 17:7674863-7674863 6
15 COSM6986214 SOX9 soft tissue,striated muscle,rhabdomyosarcoma,NS c.76A>G p.M26V 17:72121467-72121467 6
16 COSM6945139 RICTOR soft tissue,striated muscle,rhabdomyosarcoma,NS c.2898-1G>T p.? 5:38952426-38952426 6
17 COSM6986215 PTPRT soft tissue,striated muscle,rhabdomyosarcoma,NS c.2277G>T p.Q759H 20:42248779-42248779 6
18 COSM13016 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.226G>C p.E76Q 12:112450406-112450406 6
19 COSM14271 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.1508G>T p.G503V 12:112489084-112489084 6
20 COSM13014 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.214G>A p.A72T 12:112450394-112450394 6
21 COSM13013 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.205G>A p.E69K 12:112450385-112450385 6
22 COSM6986208 PTCH1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.208G>A p.A70T 9:95506593-95506593 6
23 COSM6910708 POLE soft tissue,striated muscle,rhabdomyosarcoma,NS c.5975G>C p.C1992S 12:132634215-132634215 6
24 COSM1083818 PIK3CG soft tissue,striated muscle,rhabdomyosarcoma,NS c.2638G>A p.E880K 7:106883041-106883041 6
25 COSM766 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1636C>A p.Q546K 3:179218306-179218306 6
26 COSM763 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1633G>A p.E545K 3:179218303-179218303 6
27 COSM760 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1624G>A p.E542K 3:179218294-179218294 6
28 COSM775 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.3140A>G p.H1047R 3:179234297-179234297 6
29 COSM762 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1625A>T p.E542V 3:179218295-179218295 6
30 COSM1235326 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.3023C>T p.S1008F 3:179234180-179234180 6
31 COSM6914067 PDGFRA soft tissue,striated muscle,rhabdomyosarcoma,NS c.3195G>C p.E1065D 4:54295197-54295197 6
32 COSM6964921 NTRK3 soft tissue,striated muscle,rhabdomyosarcoma,NS c.492C>A p.C164* 15:88137534-88137534 6
33 COSM580 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.181C>A p.Q61K 1:114713909-114713909 6
34 COSM585 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.183A>T p.Q61H 1:114713907-114713907 6
35 COSM564 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>A p.G12D 1:114716126-114716126 6
36 COSM569 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.37G>C p.G13R 1:114716124-114716124 6
37 COSM584 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.182A>G p.Q61R 1:114713908-114713908 6
38 COSM563 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>A p.G12S 1:114716127-114716127 6
39 COSM574 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.38G>T p.G13V 1:114716123-114716123 6
40 COSM586 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.183A>C p.Q61H 1:114713907-114713907 6
41 COSM562 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>T p.G12C 1:114716127-114716127 6
42 COSM6910706 NOTCH1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.3277T>C p.Y1093H 9:136508280-136508280 6
43 COSM6933086 NF1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.7870G>C p.A2624P 17:31357269-31357269 6
44 COSM1745010 MYOD1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.365T>G p.L122R 11:17720147-17720147 6
45 COSM521 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>A p.G12D 12:25245350-25245350 6
46 COSM516 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>T p.G12C 12:25245351-25245351 6
47 COSM532 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.38G>A p.G13D 12:25245347-25245347 6
48 COSM522 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>C p.G12A 12:25245350-25245350 6
49 COSM528 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.37G>A p.G13S 12:25245348-25245348 6
50 COSM553 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.182A>T p.Q61L 12:25227342-25227342 6

Copy number variations for Rhabdomyosarcoma from CNVD:

7 (show all 19)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32214 1 34600000 40100000 Amplification MYCL1 Rhabdomyosarcoma
2 48341 11 1 2800000 Loss HRAS Rhabdomyosarcoma
3 55467 11 532242 535550 Mutation HRAS Rhabdomyosarcoma
4 69397 12 54900000 58100000 Amplification or los s GLI Rhabdomyosarcoma
5 69949 12 56600000 58100000 Amplification CDK4 Rhabdomyosarcoma
6 69950 12 56600000 58100000 Amplification SAS Rhabdomyosarcoma
7 79876 13 79000000 101700000 Amplification C13orf25 Rhabdomyosarcoma
8 79877 13 79000000 101700000 Amplification GPC5 Rhabdomyosarcoma
9 106840 17 1 3300000 Loss HIC1 Rhabdomyosarcoma
10 106842 17 1 3300000 Loss Rhabdomyosarcoma
11 106969 17 10700000 22200000 Loss Rhabdomyosarcoma
12 110141 17 314735 515143 Loss Rhabdomyosarcoma
13 127361 19 32400000 43400000 Amplification AKT2 Rhabdomyosarcoma
14 185187 4 187100000 191154276 Loss Rhabdomyosarcoma
15 187611 4 52700000 59500000 Loss PDGFRA Rhabdomyosarcoma
16 187815 4 55095264 55146925 Amplificationlicatio n PDGFRA Rhabdomyosarcoma
17 187856 4 55524095 55606879 Amplificationlicatio n C-Kit Rhabdomyosarcoma
18 239020 8 36500000 45600000 Amplification FGFR1 Rhabdomyosarcoma
19 253524 9 43600000 47300000 Loss Rhabdomyosarcoma

Expression for Rhabdomyosarcoma

Search GEO for disease gene expression data for Rhabdomyosarcoma.

Pathways for Rhabdomyosarcoma

GO Terms for Rhabdomyosarcoma

Biological processes related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 BRCA1 FOXO1 IGF2 MYOD1 PAX3 PAX7
2 positive regulation of transcription, DNA-templated GO:0045893 9.63 BRCA1 FHL2 FOXO1 MYOD1 PAX3 TP53
3 muscle organ development GO:0007517 9.61 MYOD1 PAX3 PAX7
4 striated muscle cell differentiation GO:0051146 9.49 IGF2 MYOD1
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 BRCA1 TP53
6 regulation of gene expression by genetic imprinting GO:0006349 9.46 BRCA1 IGF2
7 negative regulation of apoptotic process GO:0043066 9.43 ALK FHL2 FOXO1 IGF2 PAX7 TP53
8 enamel mineralization GO:0070166 9.4 FOXO1 STIM1
9 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 9.37 MIR29B2 MIR29C
10 negative regulation of circulating fibrinogen levels GO:0061754 9.26 MIR29B2 MIR29C
11 regulation of DNA methylation GO:0044030 8.8 BRCA1 MIR29B2 MIR29C

Molecular functions related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.02 BRCA1 FOXO1 MYOD1 SLC22A18 TP53

Sources for Rhabdomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....